Description of Business and Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties

The Company’s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Net revenue:
Product revenue (1)	$	46,758	$	29,278	$	89,986	$	58,004
Services (2)		36		278		420		500
Royalties (3)		25,592		19,055		48,243		30,733
Total net revenue	$	72,386	$	48,611	$	138,649	$	89,237

_________________________

(1)Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.

(2)Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 9) for UT as well as arrangements with other collaboration partners. See Note 9 – Collaboration, Licensing and Other Arrangements.

(3)Amounts represent royalties on UT’s net revenue from Tyvaso DPI sales.

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Cost of goods sold and cost of revenue:
Product revenue	$	20,377	$	13,995	$	38,628	$	30,023
Services		—		242		347		427
Total cost of goods sold and cost of revenue	$	20,377	$	14,237	$	38,975	$	30,450

Schedule of Restrictions on Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets that sum to amounts reported on the condensed consolidated statements of cash flows (in thousands):

	June 30, 2024		December 31, 2023
Cash and cash equivalents	$	96,643	$	238,480
Restricted cash		732		—
Total cash, cash equivalents and restricted cash	$	97,375	$	238,480